Evidence map›Paper›PMID 31929673›Full record

ArticleProceedings of SPIE--the International Society for Optical Engineering2019

On the use of fluorescein-based contrast agents as analogs to MRI-gadolinium agents for imaging brain tumors.

Scott C Davis, Margaret R Folaron, Rendall R Strawbridge, Caroline Filan, Kimberley S Samkoe, David W Roberts

Open access · greenAbstract read
In one paragraph

Article in Proceedings of SPIE--the International Society for Optical Engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. The use of the sodium fluorescein and YELLOW 560 nm filter for the resection of pediatric posterior fossa lesions.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Scott C DavisThayer School of Engineering, Dartmouth College, 14 Engineering Dr., Hanover, NH USA 03755-8001.
Margaret R FolaronThayer School of Engineering, Dartmouth College, 14 Engineering Dr., Hanover, NH USA 03755-8001.
Rendall R StrawbridgeThayer School of Engineering, Dartmouth College, 14 Engineering Dr., Hanover, NH USA 03755-8001.
Caroline FilanThayer School of Engineering, Dartmouth College, 14 Engineering Dr., Hanover, NH USA 03755-8001.
Kimberley S SamkoeThayer School of Engineering, Dartmouth College, 14 Engineering Dr., Hanover, NH USA 03755-8001.
David W RobertsDepartment of Surgery, Geisel School of Medicine, 1 Rope Ferry Rd., Hanover, NH USA 03755.
Dartmouth College · USDartmouth–Hitchcock Medical Center · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Coregistered Fluorescence-Enhanced Resection of Malignant GliomaR01NS052274 · NINDS · DARTMOUTH-HITCHCOCK CLINIC · PI ROBERTS, DAVID W · 2007 to 2018
$4.6M
MRI fluorescence tomography for quantifying tumor receptor concentration in vivoR01CA184354 · NCI · DARTMOUTH COLLEGE · PI DAVIS, SCOTT C · 2014 to 2018
$2.6M
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA184354NINDS NIH HHS R01 NS052274
6 · The paper itself

Abstract

Magnetic resonance imaging (MRI) of gadolinium (Gd)-based contrast agents plays a central role in managing the treatment of intracranial tumors. These images are involved in diagnosis, surgical planning, surgical navigation, and postoperative assessment of extent of resection. Replicating the information from Gd-MRI in the visual surgical field using fluorescent agents that behave similar to gadolinium in vivo would represent a major advance for surgical intervention of these tumors, and could provide robust compensation information to update pre-operative MRI images during surgery. In this paper, we examine the uptake of a Gd-based contrast agent in orthotopic tumor models and compare this behavior to two fluorescein-based contrast agents; specifically, clinical-grade sodium fluorescein (NaFl) and a 900 Da pegylated form of fluorescein. We show that the pegylated form of fluorescein is a more promising Gd-analog candidate.

Indexed as

brain tumorcontrast agentsfluorescence guided surgerygadoliniumgliomaMRI

Identifiers

PMID31929673
PMCPMC6953720
OpenAlexW2921854866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.